356 results about "Car t cells" patented technology

The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.

The invention discloses a method for knocking out a PD-1 gene by utilizing a CRISPR/Cas9 technology to construct an MSLN-targeted novel CAR-T cell. According to the method, a CAR-T cell is synchronously infected with a virus solution carrying sgRNA and Cas9-HF nuclease of a human PD-1 gene by utilizing the CRISPR/Cas9 technology to knock out the human PD-1 gene, so that the MSLN-targeted novel CAR-T cell is obtained. The novel CAR-T cell can be used for preparing a preparation used for treating solid tumors. A preparation method is simple in step, and the obtained CAR-T cell has high killing rate for solid tumor cells.

The invention discloses a CAR-T transgene vector based on replication defective recombinant lentivirus. The CAR-T transgene vector comprises an original nuclear replicon pUCOri sequence, a resistance gene AmpR sequence containing ampicillin, a virus replicon SV40 Ori sequence, a lentivirus packaging cis element, ZsGreen1 green fluorescent protein, an IRES ribosome binding sequence, a human EF1 alpha promoter , a chimeric antigen receptor of second-generation CAR or third-generation CAR and a regulating element, wherein the original nuclear replicon pUCOri sequence is used for plasmid replication; the resistance gene AmpR sequence is used for massively proliferating target strains; the virus replicon SV40 Ori sequence is used for enhancing replication in eukaryocyte; the lentivirus packaging cis element is used for lentivirus packaging; the ZsGreen1 green fluorescent protein is used for expressing green fluorescent for eukaryocyte; the IRES ribosome binding sequence is used for jointly transcribing and expressing protein; the human EF1 alpha promoter is used for conducting eukaryotic transcription on antigen receptor genes; the chimeric antigen receptor is used for forming the second-generation CAR or the third-generation CAR integrating recognition, transfer and start; the regulating element is used for enhancing expression efficiency of transgenes and used after eWPRE-enhanced type woodchuck hepatitis b virus is transcribed. Besides, the invention further discloses a construction method and application of the vector. By means of the CAR-T transgene vector and the construction method and application of the vector, secretion of cell factors and an in vitro killing effect of CAR-T cells can be remarkably improved, and the clinical treatment effect is remarkable.

The present invention discloses a novel chimeric antigen receptor and applications thereof, wherein the novel chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a transmembrane domain and an intracellular signal domain, and comprises a 4-1BB signal peptide and/or a 4-1BB molecular transmembrane domain. According to the present invention, a variety of chimeric antigenreceptor nucleic acid sequences are separated and purified, the chimeric antigen receptor specifically for CD19 malignant tumor antigens and the CAR-T cells are provided, and the blood cell line malignant tumor killing test results show that the tumor-cell-targeting ability of immune cells is significantly enhanced, and the tumor cell killing activity is enhanced.

The invention relates to a chimeric antigen receptor of a targeted GPC3 (Glypican 3) and an application thereof. Specifically, the invention provides a polynucleotide sequence, wherein the polynucleotide sequence is selected from: polynucleotide sequences (1) containing a coding sequence of a CD8 antigen leading peptide, a coding sequence of an anti-GPC3 single-chain antibody, a coding sequence of a human CD8 alpha hinge region, a coding sequence of a human CD8 transmembrane region, a coding sequence of a human 41BB intracellular region, and a coding sequence of a human CD3 zeta intracellular region, and a coding sequence of an optional fragment of an EGFR (Epidermal Growth Factor Receptor) sequence containing an extracellular domain III and an extracellular domain IV, wherein the coding sequences are sequentially connected; and complementary sequences (2) of the polynucleotide sequences (1). The invention provides a CAR (chimeric antigen receptor) coded by the polynucleotide sequences and a T cell expressing the CAR. The prepared CAR-T cell has a function of strongly killing a specific tumor cell, and the kill effectiveness is more than 90% under the condition that the effector-target ratio is 20:1.

The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.

Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting cells that express elevated levels of antigen (e.g., cancer cells) with CAR T-cell therapies are provided.

The invention provides a BCMA-based (B cell maturation antigen-based) chimeric antigen receptor, comprising following cis-form cascade domains: CD8a leader region, scFv fragment BCMA scFv of anti-BCMA antibody, CD8a hinge region and transmembrane region, CD28 intracellular signal domain and CD3 Zeta intracellular signal domain; the CD3 Zeta intracellular signal domain is wild CD3 Zetaintracellular signal domain or mutant CD3 Zeta mut intracellular signal domain; the BCMA-based chimeric antigen receptor can enhance anti-apoptotic capability of T-cells and enhance CAR T-cell and antigen bonding and signal conduction; T-cells with the BCMA-based chimeric antigen receptor show good tumor targeting performance in in-vivo experiments, tumors diminish significantly after two weeks of dosage, and the T-cells have excellent therapeutic effect in vivo.

The invention provides a CD19 targeted CAR (chimeric antigen receptor)-T cell, a preparation method and an application and relates to the field of immune cells. The activation capacity of T cells in CAR-T cell therapy can be improved, the problem of insufficient transfection efficiency can be solved, and the CAR-T cell has a high killing capacity for CD19. The CD19 targeted CAR-T cell expresses a CD19 targeted CAR gene on surface, and the CD19 targeted CAR gene is formed by connecting a single-chain antibody CD19ScFv of CD19, a hinge region and a transmembrane region of CD8, an intracellular signal structure of CD28, an intracellular signal structure of 4-1BB and an intracellular signal structural domain of CD3zeta in series, and the base sequence of the CD19 targeted CAR gene is shown as SEQ ID NO:2.

The invention belongs to the technical field of biology, and discloses a polypeptide containing two chimeric antigen receptor structures, nucleic acid for coding the polypeptide, a modified T lymphocyte, and a preparation method and application of the T lymphocyte. The polypeptide provided by the invention contains the two chimeric antigen receptor (CAR) structures, wherein one chimeric antigen receptor structure specifically targets a tumor cell, and the other one specifically targets a normal B lymphocyte, so that a CAR-T cell is effectively amplified through recognizing the B lymphocyte ofa blood circulation system, and more CAR-T cells arrive at a solid tumor part so as to specifically kill the tumor cell for improving a treatment effect on the solid tumor. The polypeptide further comprises an ScFv structure of an anti-PD-L1 monoclonal antibody, and the CAR-T cells can simultaneously secrete a PD-L1 monoclonal antibody which interdicts an immunosuppressive action medicated by a PD1/PDL1 signal pathway and T cell failure, so that the treatment effect on the solid tumor is improved, the functional activity of immune cells in vivo is prolonged at the same time, and finally the tumor recurrence is retarded and even avoided.

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.

The invention relates to a chimeric antigen acceptor of a target BCMA (B cell maturation antigen). The chimeric antigen acceptor comprises an extracellular identification region, a hinge region, a transmembrane region and an intracellular signal region, wherein the extracellular identification region has a BCMA resisting nanometer antibody sequence, and the BCMA resisting nanometer antibody sequence is a heavy-chain variable region sequence combining with BCMA and from alpacas. More specifically, the BCMA resisting nanometer antibody sequence is BCMA monoclonal antibody B1 or B65, the amino acid sequence of the B1 is as shown in SEQID NO.1, and the amino acid sequence of the B65 is as shown in SEQID NO.2. According to the chimeric antigen acceptor disclosed by the invention, compared witha traditional mouse-derived SCFV or humanized SCFV, the nanometer antibody from the alpacas is used, and has small molecule quantity and immunogenicity, the possibility that CAR-T cells prepared on the base of the nanometer antibody produce HAMA effects in vivo is smaller, the remaining time of the CAR-T cells in vivo can be longer, the CAR-T cells pass through BCMA protein on the surfaces of target tumor cells and activate signal channels at the downstream part of T cells, the capacity for killing tumor cells having BCMA target points is given to the T cells, and BCMA positive blood tumor canbe efficiently and specifically treated.

The invention relates to an embedded antigen receptor based on CD30 and application thereof, and particularly relates to a building method of an embedded antigen receptor T (CAR-T) cell technology based on a tumor specific target site CD30 and application thereof in anti-tumor treatment. The embedded antigen receptor is prepared by connecting an antigen binding structural domain, a transmembrane structural domain, a costimulatory signal conducting region and a CD3 zeta signal conducting structural domain in series, wherein the antigen binding structural domain is combined with tumor-surface antigen, and the tumor-surface antigen is CD30. By adopting the embedded antigen receptor, specific gene transformation on a single chain antibody of the tumor-surface antigen CD30 is carried out, and because of the transformed antibody, the binding force of the antigen-antibody is stronger, and the mutation difficultly occurs; compared with other embedded antigen receptors and other tumor antigens, the embedded antigen receptor has a better effect, and the expression quantity of the target site is high, so that an immunization effect of CAR-T cells is enhanced, and a treatment effect on the CAR-T cells is enhanced.

The invention relates to a new chimeric antigen receptor (CAR) molecule containing an intracellular segment of DAP 10 protein, nucleic acid for encoding the CAR molecule, cells for expressing the CARmolecule, and use of the CAR molecule in preparation of medicines for treating tumors. The CAR molecule provided by the invention is realized by introducing the intracellular segment of the DAP 10 protein into the traditional second generation of CAR molecule; a downstream signaling pathway of the DAP10 of the T cells is activated after binding of the CAR molecule and a target antigen, so that thekilling effect of the corresponding CAR T cells on solid tumor in vivo and in vitro is improved, and the proliferation and survival abilities of the CAR T cells are enhanced.

The invention relates to an embedded antigen receptor based on CD22 and application thereof, and particularly relates to a building method of an embedded antigen receptor T (CAR-T) cell technology based on a tumor specific target site CD22 and application thereof in anti-tumor treatment. The embedded antigen receptor is prepared by connecting an antigen binding structural domain, a transmembrane structural domain, a costimulatory signal conducting region and a CD3 zeta signal conducting structural domain in series, wherein the antigen binding structural domain is combined with tumor-surface antigen, and the tumor-surface antigen is CD22. By adopting the embedded antigen receptor, specific gene transformation on a single chain antibody of the tumor-surface antigen CD22 is carried out, and because of the transformed antibody, the binding force of the antigen-antibody is stronger, and the mutation difficultly occurs; compared with other embedded antigen receptors and other tumor antigens, the embedded antigen receptor has a better effect, and the expression quantity of the target site is high, so that an immunization effect of CAR-T cells is enhanced, and a treatment effect on the CAR-T cells is enhanced.

The invention belongs to the technical field of biology and particularly relates to a chimeric antigen receptor based on a CD276 antibody, a lentivirus expression vector and application thereof. The chimeric antigen receptor is CD276-28z-CAR chimeric antigen receptor, a CD276-BBz-CAR or CD276-28BBz-CAR chimeric antigen receptor, the amino acid sequence of the CD276-28z-CAR chimeric antigen receptor is shown in SEQ ID NO.1, the amino acid sequence of the CD276-BBz-CAR chimeric antigen receptor is shown in SEQ ID NO.2, and the amino acid sequence of the CD276-28BBz-CAR chimeric antigen receptoris shown in SEQ ID NO.3. The chimeric antigen receptor is constructed by adopting an scFv sequence with higher affinity, so that generated CAR-T cells can effectively kill tumor cells.

The present invention pertains to engineered immortalized T-cell lines, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immortalized T-cell lines of the invention are characterized in that the expression of endogenous T-cell receptors (TCRs) and beta 2-microglobulin (B2M) is inhibited, e.g., by using an endonuclease able to selectively inactivate the TCR and B2M genes in order to render the immortalized T-cells non-alloreactive. In addition, expression of immunosuppressive polypeptide can be performed on those engineered immortalized T-cells in order to prolong the survival of these T-cells in host organisms. Such engineered immortalized T-cells are particularly suitable for allogeneic transplantations, especially because it reduces both the risk of rejection by the host's immune system and the risk of developing graft versus host disease. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immortalized T-cells for treating cancer, infections and auto-immune diseases.

The invention relates to a method for preparing PD-1 and LAG3 double knockout CD19 CAR-T cells by Cas9/RNP. The method comprises the following steps: mixing sgRNA and Cas9 protein for knocking out PD-1 and LAG3 genes with an electroporation transformation reagent, and adding the mixture into CD4+/CD8+ cells for electroporation transformation; transfecting CD4+/CD8+ positive cells with CD19 CAR lentivirus; and screening, and culturing and amplifying transfected T cells, so as to obtain the PD-1 and LAG3 double knockout CD19 CAR-T cells. The method, adopting a Cas9/RNP gene editing system, improves the transfection efficiency and the expression efficiency and time of transgenes, simplifies the preparation process of CAR-T cells, and improves the feasibility and increases the load of the system. In addition, the method is free of transfection reagents when the PD-1 and LAG3 double genes are knocked out, and thus the safety is higher.

The invention relates to the fields of immunology and molecular biology, in particular to a method for preparing chimeric antigen receptor-T (CAR-T) cells, and the prepared CAR-T cells and application thereof. According to the method for preparing the CAR-T cells, the CAR-T cells are obtained by enabling CD3 positive T cells to be infected by CAR-containing virus. The invention also discloses the prepared CAR-T cells and a composition containing the CAR-T cells. The method for preparing the CAR-T cells enables the CD3 positive T cells to be infected by the CAR-containing virus so as to obtain the CAR-T cells, thus being capable of realizing the industrial production and preparation of the CAR-T cells used for individualized treatment; the prepared CAR-T cells eliminate the repellency between individuals; the CAR-T cells prepared by the method are better in effectiveness and higher in safety. The invention also provides the application of the CAR-T cells in preparation of medicine for treating or preventing cancers.